Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis-Reference-Cited by-同舟云学术

Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Published:2017-03-08 Issue:2 Volume:8 Page:251-273
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Kay Stephen,Strickson Amanda^ORCID,Puelles Jorge,Selby Ross,Benson Eugene,Tolley Keith

Funder

Takeda Development Center, Europe

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13300-017-0245-8.pdf

Reference47 articles.

1. European Medicines Agency. CHMP assessment report. Vipidia. EMA/CHMP/207780/2013. 25 July 2013.

2. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46–55.

3. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009;25(10):2361–71.

4. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733–45.

5. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011;28(11):1352–61.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on: Association of sulfonylureas with the risk of dementia: A population‐based cohort study;Journal of the American Geriatrics Society;2024-01-20

2. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications;Life;2023-04-14

3. KAIYU ZHENGYUAN POWDER AFFECTS EPITHELIAL-MESENCHYMAL TRANSITION AND APOPTOSIS OF PAPILLARY THYROID CARCINOMA THROUGH ER/PI3K/AKT SIGNALING PATHWAY;ACTA MEDICA MEDITERR;2023

4. Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes;Diabetes Therapy;2022-07-06

5. Type II diabetes mellitus: a review on recent drug based therapeutics;Biomedicine & Pharmacotherapy;2020-11